semaglutide + tirzepatide

Semaglutide + tirzepatide is a combination of two incretin-based pharmaceutical agents, each with distinct but overlapping mechanisms for glycemic control and weight management. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, while tirzepatide acts as both a GLP-1 receptor agonist and a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Both drugs stimulate insulin secretion in response to elevated blood glucose, suppress glucagon release, slow gastric emptying, reduce appetite via central nervous system pathways, and promote weight loss. Tirzepatide’s dual action on GIP and GLP-1 receptors may provide additional metabolic benefits compared to single-agent therapy. While both are approved individually for type 2 diabetes and chronic weight management, their combined use is not currently recommended by regulatory agencies due to potential safety concerns such as intensified gastrointestinal side effects or increased risk of serious adverse events[1][2]. Some clinicians have explored off-label or compounded co-administration in select patients under close supervision; however, this approach lacks robust clinical trial evidence for efficacy or safety.